LeonaBio reported Q1 2026 results and progress on its Phase 3 trial of lasofoxifene, targeting treatment-resistant ER+, HER2-, ESR1-mutated metastatic breast cancer. The company plans to complete enrollment by Q4 2026 and expects topline data in the second half of 2027. LeonaBio is also preparing a Phase 2 trial for ATH-1105 in ALS patients for late 2026. Financially, it ended Q1 with $67.7 million in cash and investments but posted a $32.9 million net loss due to increased R&D and administrative expenses.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
